PMEF
URGN icon

Point72 Middle East FZE’s UroGen Pharma URGN Stock Holding History

Point72 Middle East FZE’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,941
Closed -$83.2K – 1905
2023
Q3 		$83.2K Buy
+5,941
New +$95.4K ﹤0.01% 1178

Other funds holding URGN

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Menora Mivtachim Holdings
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Harel Insurance Investments & Financial Services
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
Migdal Insurance & Financial Holdings
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.65% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Point72 Middle East FZE's URGN Position: Q4 2023 in Review

Point72 Middle East FZE sold out of UroGen Pharma (URGN) in Q4 2023, closing a stake of 5,941 shares — an estimated $83.2K sold.

Point72 Middle East FZE first reported a position in URGN in Q3 2023 and held it in 1 quarter. The position peaked at $83.2K in Q3 2023. 105 funds tracked by Wall St. Rank hold URGN as of Q4 2023.

  • Point72 Middle East FZE reported no remaining UroGen Pharma position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 5,941 UroGen Pharma shares in Q4 2023, an estimated $83.2K.
  • Point72 Middle East FZE first reported a position in UroGen Pharma in Q3 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's UroGen Pharma position peaked at $83.2K in Q3 2023.
  • 105 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.